NeuBase Therapeutics, Inc (NBSE)

Etorro trading 970x250
NeuBase Therapeutics, Inc (NBSE) Logo

About NeuBase Therapeutics, Inc

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington’s disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. Address: 700 Technology Drive, Pittsburgh, PA, United States, 15219

NeuBase Therapeutics, Inc News and around…

Latest news about NeuBase Therapeutics, Inc (NBSE) common stock and company :

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
17 Nov, 2021 FinancialContent

Gainers Rockwell Medical (NASDAQ:RMTI) shares rose 47.27% to $0.71 during Wednesday's pre-market session. The ...

The Math Shows ITOT Can Go To $116
11 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Total US.

NeuBase to Present at the Jefferies London Healthcare Conference
03 Nov, 2021 Yahoo! Finance

PITTSBURGH, Nov. 03, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present in person a corporate overview at the Jefferies London Healthcare Conference being held November 16 - 18. Jefferies London Healthcare Conferenc

Quite a few insiders invested in NeuBase Therapeutics, Inc. (NASDAQ:NBSE) last year which is positive news for shareholders
01 Nov, 2021 Yahoo! Finance

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Friday Sector Laggards: Biotechnology, Publishing Stocks
15 Oct, 2021 FinancialContent

In trading on Friday, biotechnology shares were relative laggards, down on the day by about 1.1%. Helping drag down the group were shares of Aerovate Therapeutics, off about 15.4% and shares of NeuBase Therapeutics down about 8.4% on the day.

VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States
05 Oct, 2021 Yahoo! Finance

Amos Ron to Retire as CFO and Will Continue to Serve as Corporate Secretary, Advisor to VBL Sam Backenroth, Chief Financial Officer, VBL Therapeutics Sam Backenroth, Chief Financial Officer, VBL Therapeutics TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately. Mr. Backenroth is an accomplished corporate finance veteran with demonstrated success in

NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference
28 Sep, 2021 FinancialContent
NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit 
15 Sep, 2021 FinancialContent
NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
15 Sep, 2021 Yahoo! Finance

PITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held September 20 – 23. Oppenheimer Fall

NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology Officer
14 Sep, 2021 FinancialContent
Peek Under The Hood: VXF Has 16% Upside
09 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Extended Market ETF (VXF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $218.80 per unit.

NeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment Conference
01 Sep, 2021 FinancialContent
What Type Of Shareholders Make Up NeuBase Therapeutics, Inc.'s (NASDAQ:NBSE) Share Registry?
31 Aug, 2021 Yahoo! Finance

If you want to know who really controls NeuBase Therapeutics, Inc. ( NASDAQ:NBSE ), then you'll have to look at the...

NeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating Highlights
12 Aug, 2021 FinancialContent
Add Up The Parts: ITOT Could Be Worth $111
05 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Total US.

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Tuesday
27 Jul, 2021 FinancialContent

During Tuesday's morning session, 216 companies made new 52-week lows. Noteworthy Points: Alibaba Group ...

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Wednesday
14 Jul, 2021 FinancialContent

Wednesday morning saw 57 companies set new 52-week lows. Noteworthy Points: Campbell Soup (NYSE:CPB) was ...

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
08 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
07 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

We Did The Math FDM Can Go To $75
02 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $74.98 per unit.

We're Hopeful That NeuBase Therapeutics (NASDAQ:NBSE) Will Use Its Cash Wisely
30 Jun, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth
08 Jun, 2021 FinancialContent
NeuBase Therapeutics Announces Speakers for Virtual R&D Day Taking Place on June 8th
02 Jun, 2021 FinancialContent
NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer
25 May, 2021 FinancialContent

Expansion of management team continues with addition of an industry leader with deep experience in business development, licensing, and strategy in the life-science industry

NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer
20 May, 2021 FinancialContent

Expansion of management team to support the Company’s advancement of its first drug candidate into clinical trials next year and growth of therapeutic pipeline

NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021
14 May, 2021 FinancialContent
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
14 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

NeuBase Therapeutics, Inc (NBSE) is a NASDAQ Common Stock listed in , ,

970x250